Holen Sie sich die Stockscreener-App
1.42
2.15%
0.0299
Schlusskurs vom Vortag:
$1.3901
Offen:
$1.409
24-Stunden-Volumen:
2,519
Relative Volume:
0.19
Marktkapitalisierung:
$69.65M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-9.51M
KGV:
-7.4737
EPS:
-0.19
Netto-Cashflow:
$-10.96M
1W Leistung:
+2.16%
1M Leistung:
-4.05%
6M Leistung:
-39.32%
1J Leistung:
+2.16%
1-Tages-Spanne:
$1.40
$1.42
1-Wochen-Bereich:
$1.3901
$1.45
52-Wochen-Spanne:
$1.12
$2.55
Medicinova Inc Stock (MNOV) Company Profile
Firmenname
Medicinova Inc
Sektor
Branche
Telefon
858-373-1500
Adresse
4275 EXECUTIVE SQUARE, LA JOLLA, CA
Vergleichen Sie MNOV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MNOV
Medicinova Inc
|
1.42 | 69.65M | 0 | -9.51M | -10.96M | -0.19 |
|
ONC
Beone Medicines Ltd Adr
|
256.49 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.81 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2213 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.32 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
495.37 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Medicinova Inc Stock (MNOV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-03-10 | Eingeleitet | Maxim Group | Buy |
| 2019-03-25 | Fortgesetzt | B. Riley FBR | Buy |
| 2018-03-28 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-04-18 | Eingeleitet | Credit Suisse | Outperform |
| 2013-01-04 | Bestätigt | Ladenburg Thalmann | Buy |
| 2012-05-24 | Herabstufung | MLV & Co | Buy → Hold |
| 2011-10-18 | Bestätigt | MLV Capital | Buy |
| 2011-06-22 | Eingeleitet | Global Hunter Securities | Buy |
| 2010-05-12 | Eingeleitet | Wedbush | Outperform |
| 2008-11-12 | Bestätigt | Ladenburg Thalmann | Buy |
| 2008-05-15 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-07-09 | Eingeleitet | Punk, Ziegel & Co | Buy |
Alle ansehen
Medicinova Inc Aktie (MNOV) Neueste Nachrichten
Type 2 Diabetes Market to Expand Significantly by 2034, States DelveInsight Report | Eli Lilly and Company, Regor Pharma, AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova - The Globe and Mail
StockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV) - Defense World
MediciNova: Q1 Earnings Snapshot - San Antonio Express-News
Barclays PLC Purchases 12,800 Shares of MediciNova, Inc. (NASDAQ:MNOV) - Defense World
MediciNova (NASDAQ:MNOV) Now Covered by StockNews.com - Defense World
StockNews.com Initiates Coverage on MediciNova (NASDAQ:MNOV) - Defense World
Geode Capital Management LLC Raises Position in MediciNova, Inc. (NASDAQ:MNOV) - Defense World
MediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.com - Defense World
We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth - Yahoo
MediciNova (NASDAQ:MNOV) Coverage Initiated at StockNews.com - Defense World
MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025 - The Manila Times
MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025 - GlobeNewswire
MediciNova Secures Spotlight at Exclusive Healthcare Conference: CEO to Reveal Latest Pipeline Progress - Stock Titan
Meta CEO Mark Zuckerberg takes the stand in historic antitrust trial - The Globe and Mail
MediciNova’s (MNOV) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Texas Instruments (TXN) Stock Trades Down, Here Is Why - The Globe and Mail
First Patient Enrolled in NIH-Funded Expanded Access - GlobeNewswire
First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients - TradingView
This Stock Has More Than Doubled Already in 2025. Is It a Buy? - The Globe and Mail
MediciNova (NASDAQ:MNOV) Now Covered by Analysts at StockNews.com - Defense World
MEDICINOVA INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus
Why AppLovin (APP) Shares Are Trading Lower Today - The Globe and Mail
MediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at StockNews.com - Defense World
Carter's (CRI): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail
3 Reasons to Avoid CSX and 1 Stock to Buy Instead - The Globe and Mail
Idiopathic Pulmonary Fibrosis Management Market Top Companies - openPR
Y Intercept Hong Kong Ltd Makes New $78,000 Investment in MediciNova, Inc. (NASDAQ:MNOV) - Defense World
Should You Forget Tesla and Buy 2 Artificial Intelligence (AI) Stocks Right Now? - The Globe and Mail
Pulmonary Fibrosis Therapeutics Market Size in the 7MM - openPR
MKS Instruments to Participate in Cantor Fitzgerald Global Technology Conference - The Globe and Mail
Idiopathic Pulmonary Fibrosis Management Market Key Players - openPR
D. Boral Capital Reiterates Buy Rating for MediciNova (NASDAQ:MNOV) - The AM Reporter
MediciNova (NASDAQ:MNOV) Issues Earnings Results - MarketBeat
MediciNova (NASDAQ:MNOV) Releases Quarterly Earnings Results, Meets Estimates - MarketBeat
MediciNova (MNOV) to Release Quarterly Earnings on Thursday - MarketBeat
MediciNova (MNOV) Projected to Post Quarterly Earnings on Thursday - Defense World
Quantum Biopharma Engages Enterprise Canada and Empire Market Ventures to Lead Public Communications and Investor Awareness Programs - The Globe and Mail
US Exchange Penny Stocks To Watch In January 2025 - Yahoo Finance
Finanzdaten der Medicinova Inc-Aktie (MNOV)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.30%
3.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):